BASF sells Shreveport site

BASF has signed an agreement to sell its manufacturing facility in
The agreement includes the sale of the related contract manufacturing business for finished pharmaceuticals and the transfer of 150 employees from BASF to Dr Reddy’s Laboratories
The
BASF says it is selling the site and related business in order to concentrate on core businesses in its Care Chemicals division, which include custom synthesis services, excipients and active ingredients for the pharmaceuticals industry.
‘BASF’s contract manufacturing activity for finished pharmaceuticals is limited to North America and not linked to the technological growth areas of the company’s Pharma Ingredients and Services business,’ said Martin Widmann, head of BASF’s Pharma Ingredients and Services global business unit. ‘We assessed a variety of strategic options, but ultimately concluded that a divestiture is the best scenario not only for BASF but also for the future of the
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Radio wave weapon knocks out drone swarms
Probably. A radio-controlled drone cannot be completely shielded to RF, else you´d lose the ability to control it. The fibre optical cable removes...